◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Fennec Pharmaceuticals Inc.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item FY 2024Dec 31, 2024 FY 2023Dec 31, 2023 FY 2022Dec 31, 2022 FY 2021Dec 31, 2021
Total Revenue 47.5M 21.3M 1.5M 0.00
Operating Revenue 47.5M 21.3M 1.5M 0.00
Cost Of Revenue 3.2M 1.3M 86,000 0.00
Gross Profit 44.4M 20.0M 1.4M 0.00
Selling General And Administration 41.5M 32.7M 20.5M 12.2M
General And Administrative Expense 23.1M 20.6M 17.7M 12.2M
Research And Development 307,000 56,000 3.5M 5.0M
Depreciation And Amortization In Income Statement 89,000 287,000 149,000 16,000
Operating Expense 41.9M 33.1M 24.2M 17.2M
Operating Income 2.5M -13.1M -22.7M -17.2M
EBIT 4.0M -12.7M -22.7M -17.2M
Interest Expense 4.1M 3.4M 978,000 126,000
Interest Expense Non Operating 4.1M 3.4M 978,000 126,000
Interest Income 1.7M 441,000 195,000 54,000
Interest Income Non Operating 1.7M 441,000 195,000 54,000
Net Interest Income -2.4M -3.0M -783,000 -88,000
Other Income Expense -163,000 -34,000 -193,000 -35,000
Gain On Sale Of Security -163,000 -34,000 -193,000 -35,000
Pretax Income -71,000 -16.0M -23.7M -17.3M
Tax Provision 365,000 0.00 -- --
Tax Effect Of Unusual Items -34,230 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -436,000 -16.0M -23.7M -17.3M
Net Income From Continuing Operation Net Minority Interest -436,000 -16.0M -23.7M -17.3M
Net Income Including Noncontrolling Interests -436,000 -16.0M -23.7M -17.3M
Net Income Common Stockholders -436,000 -16.0M -23.7M -17.3M
Net Income -436,000 -16.0M -23.7M -17.3M
EBITDA 4.8M -12.4M -22.6M -17.2M
Normalized EBITDA 5.0M -12.3M -22.4M -17.2M
Reconciled Depreciation 800,000 0.00 149,000 16,000
Basic EPS 0.00 -0.60 -0.90 -0.67
Diluted EPS 0.00 -0.60 -0.90 -0.67
Basic Average Shares 27.3M 26.6M 26.3M 26.0M
Diluted Average Shares 27.3M 26.6M 26.3M 26.0M
Total Unusual Items -163,000 -34,000 -193,000 -35,000
Total Unusual Items Excluding Goodwill -163,000 -34,000 -193,000 -35,000
Tax Rate For Calcs 0.21 0.00 0.00 0.00
Normalized Income -307,230 -16.0M -23.5M -17.3M
Amortization 89,000 287,000 149,000 16,000
Amortization Of Intangibles Income Statement 89,000 287,000 149,000 16,000
Depreciation Amortization Depletion Income Statement 89,000 287,000 149,000 16,000
Diluted NI Availto Com Stockholders -436,000 -16.0M -23.7M -17.3M
Net Income Continuous Operations -436,000 -16.0M -23.7M -17.3M
Net Non Operating Interest Income Expense -2.4M -3.0M -783,000 -88,000
Other Gand A 23.1M 20.6M 17.7M 12.2M
Reconciled Cost Of Revenue 2.5M 1.5M 86,000 0.00
Selling And Marketing Expense 18.4M 12.1M 2.8M 0.00
Total Expenses 45.1M 34.3M 24.3M 17.2M
Total Operating Income As Reported 2.6M -12.8M -22.6M -17.2M
Total Other Finance Cost 89,000 287,000 149,000 16,000
Line Item FY 2024Dec 31, 2024 FY 2023Dec 31, 2023 FY 2022Dec 31, 2022 FY 2021Dec 31, 2021
Cash And Cash Equivalents 26.6M 13.3M 23.8M 21.1M
Cash Cash Equivalents And Short Term Investments 26.6M 13.3M 23.8M 21.1M
Accounts Receivable 12.9M 8.8M 1.5M 0.00
Receivables 12.9M 8.8M 1.5M 0.00
Inventory 1.1M 2.2M 576,000 0.00
Prepaid Assets 3.1M 2.6M 770,000 1.0M
Other Current Assets 466,000 44,000 63,000 253,000
Current Assets 44.1M 26.9M 26.7M 22.4M
Other Non Current Assets 822,000 6,000 -- --
Total Non Current Assets 822,000 6,000 211,000 27,000
Total Assets 44.9M 26.9M 26.9M 22.4M
Current Debt And Capital Lease Obligation 2,000 21,000 -- --
Accounts Payable 3.2M 3.8M 2.4M 777,000
Payables 3.2M 3.8M 2.4M 777,000
Payables And Accrued Expenses 6.7M 7.5M 4.6M 1.7M
Current Accrued Expenses 3.4M 3.8M 2.2M 877,000
Current Deferred Revenue 248,000 0.00 -- --
Current Liabilities 6.9M 7.6M 4.6M 1.7M
Long Term Debt 19.3M 30.9M 24.9M 5.0M
Long Term Debt And Capital Lease Obligation 19.3M 30.9M 24.9M 5.0M
Long Term Capital Lease Obligation -- 2,000 0.00 --
Total Non Current Liabilities Net Minority Interest 43.9M 30.9M 24.9M 5.0M
Total Liabilities Net Minority Interest 50.8M 38.5M 29.5M 6.6M
Common Stock 145.6M 144.3M 142.6M 140.8M
Capital Stock 145.6M 144.3M 142.6M 140.8M
Additional Paid In Capital 67.0M 62.1M 56.8M 53.2M
Retained Earnings -219.7M -219.2M -203.2M -179.5M
Gains Losses Not Affecting Retained Earnings 1.2M 1.2M 1.2M 1.2M
Other Equity Adjustments 1.2M 1.2M 1.2M 1.2M
Common Stock Equity -5.9M -11.6M -2.6M 15.8M
Stockholders Equity -5.9M -11.6M -2.6M 15.8M
Total Equity Gross Minority Interest -5.9M -11.6M -2.6M 15.8M
Total Capitalization 13.5M 19.3M 22.3M 20.8M
Net Tangible Assets -5.9M -11.6M -2.6M 15.8M
Tangible Book Value -5.9M -11.6M -2.6M 15.8M
Working Capital 37.2M 19.3M 22.1M 20.7M
Invested Capital 13.5M 19.3M 22.3M 20.8M
Total Debt 19.3M 31.0M 24.9M 5.0M
Net Debt -- 17.7M 1.1M --
Share Issued 27.5M 27.0M 26.4M 26.0M
Ordinary Shares Number 27.5M 27.0M 26.4M 26.0M
Allowance For Doubtful Accounts Receivable -3.8M -- -- --
Capital Lease Obligations 2,000 21,000 0.00 --
Current Capital Lease Obligation 2,000 21,000 0.00 --
Current Deferred Liabilities 248,000 0.00 -- --
Gross Accounts Receivable 16.7M -- -- --
Non Current Deferred Assets -- 6,000 211,000 27,000
Non Current Deferred Liabilities 24.6M 2,000 -- --
Non Current Deferred Revenue 24.6M 2,000 -- --
Treasury Shares Number -- 0.00 -- --
Line Item FY 2024Dec 31, 2024 FY 2023Dec 31, 2023 FY 2022Dec 31, 2022 FY 2021Dec 31, 2021
Operating Cash Flow 27.0M -17.1M -18.1M -14.2M
Cash Flow From Continuing Operating Activities 27.0M -17.1M -18.1M -14.2M
Depreciation And Amortization 800,000 0.00 -- --
Depreciation Amortization Depletion 800,000 0.00 -- --
Stock Based Compensation 5.1M 5.4M 4.1M 3.7M
Change In Working Capital 16.9M -6.8M 1.1M -932,000
Changes In Account Receivables -7.9M -7.3M -1.5M 0.00
Change In Receivables -7.9M -7.3M -1.5M 0.00
Change In Inventory 579,000 -1.6M -576,000 0.00
Change In Payables And Accrued Expense -863,000 2.0M 3.0M -693,000
Change In Payable -537,000 1.4M 1.6M -794,000
Change In Other Working Capital 24.8M -- -- --
Change In Other Current Assets 796,000 3,000 6,000 -2,000
Other Non Cash Items 211,000 287,000 282,000 282,000
Issuance Of Debt -- 5.0M 24.9M 5.0M
Repayment Of Debt -13.0M 0.00 -5.0M 0.00
Net Issuance Payments Of Debt -13.0M 5.0M 19.9M 5.0M
Issuance Of Capital Stock -- -- -- 0.00
Net Common Stock Issuance -- -- -- 0.00
Financing Cash Flow -13.6M 6.6M 20.7M 5.0M
Cash Flow From Continuing Financing Activities -13.6M 6.6M 20.7M 5.0M
Changes In Cash 13.4M -10.5M 2.7M -9.2M
Beginning Cash Position 13.3M 23.8M 21.1M 30.3M
End Cash Position 26.6M 13.3M 23.8M 21.1M
Free Cash Flow 27.0M -17.1M -18.1M -14.2M
Amortization Cash Flow 800,000 0.00 -- --
Amortization Of Intangibles 800,000 0.00 -- --
Change In Account Payable -537,000 1.4M 1.6M -794,000
Change In Accrued Expense -326,000 576,000 1.3M 101,000
Change In Prepaid Assets -505,000 104,000 264,000 -237,000
Common Stock Issuance -- -- -- 0.00
Long Term Debt Issuance -- 5.0M 24.9M 5.0M
Long Term Debt Payments -13.0M 0.00 -5.0M 0.00
Net Income From Continuing Operations -436,000 -16.0M -23.7M -17.3M
Net Long Term Debt Issuance -13.0M 5.0M 19.9M 5.0M
Net Other Financing Charges -1.9M -75,000 -131,000 -55,000
Proceeds From Stock Option Exercised 1.3M 1.7M 928,000 33,000
Provisionand Write Offof Assets 4.3M 0.00 -- --
Unrealized Gain Loss On Investment Securities 81,000 39,000 184,000 25,000
NEWS
Loading news...
TRENDING
Loading...